IMMURON LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.105 AUD | +5.00% |
|
+5.00% | +36.36% |
| Apr. 10 | Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024 | CI |
| Apr. 10 | Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18% | MT |
| Sales 2022 | 765K 496K | Sales 2023 | 1.8M 1.17M | Capitalization | 17.08M 11.07M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -1.3M | Net income 2023 | -3M -1.94M | EV / Sales 2022 | -5.1 x |
| Net cash position 2022 | 21.9M 14.18M | Net cash position 2023 | 16.97M 10.99M | EV / Sales 2023 | 0.06 x |
| P/E ratio 2022 |
-6.3
x | P/E ratio 2023 |
-4.51
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.02% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +5.00% | ||
| 1 week | +5.00% | ||
| Current month | -8.70% | ||
| 1 month | -19.23% | ||
| 3 months | +38.16% | ||
| 6 months | +43.84% | ||
| Current year | +36.36% |
1 week
0.10
0.11
1 month
0.100.14
Current year
0.070.17
1 year
0.070.17
3 years
0.070.20
5 years
0.050.95
10 years
0.050.95
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Lydeamore
CEO | Chief Executive Officer | 56 | 22-06-26 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 13-04-18 |
Joanne Casey
CTO | Chief Tech/Sci/R&D Officer | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roger Aston
BRD | Director/Board Member | 68 | 12-03-19 |
Daniel Pollock
BRD | Director/Board Member | 64 | 12-10-10 |
| Director/Board Member | 67 | 13-05-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-01 | 0.105 | +5.00% | 95 062 |
| 24-04-30 | 0.1 | 0.00% | 166,832 |
| 24-04-29 | 0.1 | -4.76% | 16,069 |
| 24-04-26 | 0.105 | 0.00% | 152,509 |
| 24-04-24 | 0.105 | +5.00% | 232,860 |
Delayed Quote Australian S.E., May 01, 2024 at 01:41 am EDT
More quotes
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects in Australia, Israel and the United States. The Company's flagship commercial products consist of Travelan and Protectyn. Travelan is an over the counter orally administered passive immunotherapeutic product indicated to reduce the risk of travelers' diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. The Company has four clinical programs -Travelan (IMM-124E), CampETEC, IMM-529 and Travelan (consumer product).
Sector
Pharmaceuticals
Calendar
2024-08-29
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +36.36% | 14.81M | |
| -4.24% | 86.85B | |
| +2.76% | 40.16B | |
| -16.98% | 31.28B | |
| +57.86% | 25.27B | |
| -16.24% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| -17.10% | 11.69B | |
| +6.89% | 8.83B |
- Stock Market
- Equities
- IMC Stock
